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po the Editor: Because patients with acute ST-segment elevation
yocardial infarction (STEMI) were excluded from early randomized
rials, only relatively short-term data from large multicenter studies
omparing drug-eluting stents (DES) with bare-metal stents (BMS) are
urrently available. Unambiguous ascertainment of long-term compliance
ith thienopyridines is problematic in STEMI, which is a matter of
erious concern (1,2), and one observational registry suggested higher late
6months) unadjusted and adjustedmortality rates in STEMI patients
ith a DES compared with those with a BMS (3). Thus, the use of a
ES in STEMI patients still remains highly controversial.
The design of the study and outcomes at 8- and 24-month
ollow-up were previously reported (4,5). Since then, all eligible
atients underwent routine clinical follow-up at 6-month intervals for
years after index intervention. All events up to 5 years were
djudicated by an independent clinical event committee that was
linded to the treatment assignments.
All analyses were conducted according to the intent-to-treat
rinciple. Event-free survival curves were generated using the Kaplan-
eier method, and survival between groups was compared using the
og-rank test. Hazard ratios (HRs) with 95% confidence intervals
CIs) were calculated using the Cox proportional hazards model.
The cumulative duration of dual antiplatelet treatment trended
onger in the tirofiban–sirolimus-eluting stent (SES) arm (182  92
ays vs. 155 105 days in the abciximab BMS group; p 0.073);
owever, 80% and 100% of patients in both groups discontinued
hienopyridines after 250 days and 360 days, respectively. Overall, use
f medications did not differ between study groups at any time point
uring follow-up. Complete follow-up information for as long as
,800 days was available for all patients.
At 5 years, the cumulative incidence of major adverse cardiac
vents (MACE) (death, myocardial infarction [MI], or target
essel revascularization) trended lower in the tirofiban-SES group
29.9% vs. 43.2%; HR: 0.63 [95% CI: 0.39 to 1.03]; p  0.067)
Fig. 1A). All-cause mortality (18.4%; 95% CI: 12% to 28%) (Fig.
A) and the composite of death or MI (21.8%; 95% CI: 14% to 32%)
Fig. 1B) were similar in the tirofiban-SES versus the abciximab-
MS group (15.9%; 95% CI: 10% to 25%, p 0.70 and 25.0%; 95%
I: 17% to 35%, p  0.58, respectively), whereas the need for target
essel revascularization remained markedly reduced (10.3% vs. 26.1%;
R: 0.37 [95% CI: 0.17 to 0.79]; p  0.007) in the tirofiban-SES
roup (Fig. 1C).
The cumulative incidence of definite, probable, or possible stent
hrombosis was 6.9% versus 7.9% in the tirofiban-SES group and
bciximab-BMS group, respectively (HR: 0.86 [95% CI: 0.29 to 2.6];
 0.78 (Fig. 1B). The cumulative incidence of definite and definite
r probable stent thrombosis also did not differ between the 2 groups. tAmong patients who were alive at 12 months, the cumulative
ncidence of death or nonfatal MI at 5 years was 11.2% in the
irofiban-SES group and 10% in the abciximab-BMS group (p 
.80 at log-rank test). Finally, excluding patients who underwent
arget vessel revascularization between 30 days and 1 year after the
ndex procedure, the cumulative incidence of death or nonfatal MI at
years was 21.5% in the tirofiban-SES and 24.7% in the abciximab-
MS group (p  0.78 at log-rank test), whereas the incidence of
eath or nonfatal MI at 5 years in patients who survived the first year
ollow-up free from target vessel revascularization was 9.7% in the
irofiban-SES group and 9.2% in the abciximab-BMS group (p 
.88; log-rank test).
Although it was open label and single center, our study is the
rst randomized controlled investigation of DES versus BMS
mplantation in the setting of STEMI patients undergoing mechan-
cal intervention.
A maintained clinical benefit for 24 months in terms of
eintervention in the previously instrumented artery with no excess
f subacute or late stent thrombosis was previously reported (5,6).
he current report extends these findings to 5-year follow-up.
Although results from randomized controlled trials are still pend-
ng (7), expert consensus recommends prolonging treatment with
spirin and thienopyridines for at least 1 year after DES placement.
mportantly, our study was conceived and conducted well before
nambiguous safety issues for DES use were raised. As a consequence,
nly relatively short duration of dual antiplatelet treatment (i.e., a
inimum of 3 months) was protocol mandated. Accordingly, approx-
mately one-half of the patients discontinued thienopyridines by 6
onths after intervention and nearly all discontinued dual antiplatelet
reatment at 1 year. Thus, long-term follow-up of this study is critical
o shed light on the safety profile of SES implantation followed by a
elatively short combined antiplatelet regimen in unselected patients
ndergoing intervention for STEMI, a currently off-label indication.
At 5-year follow-up, the cumulative incidence of death or nonfatal
I remained similar in the 2 study groups, and this held true at
andmark analysis of patients alive at 12-month follow-up. Based on
broad clinical definition of stent thrombosis, namely, the Academic
esearch Consortium classification, we likewise failed to observe an
xcess of late events in those patients assigned to receive SES
mplantation, whereas the benefit in terms of reintervention persisted
lmost unchanged after 1,800 days with no evidence of a late catch-up
henomenon. This is in keeping with the long-term results of the
andmark randomized studies that led to DES approval, whereas it
ontrasts with recent data from observational studies on acute MI
atients that questioned the long-term durability of DES benefit in
his patient/lesion subset (3,8).
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November 10, 2009:1900–1Importantly, it remains possible that our reassuring observations
ay have a type II error due to the small sample size. Therefore,
hile reassuring, our results cannot lend support to unrestricted
se of SES in STEMI patients, because a probably small yet
otentially sizable risk of late adverse events in patients treated
ith SES cannot be excluded.
We conclude that at 5-year follow-up, a strategy of SES
mplantation in patients undergoing treatment for STEMI re-
ained superior in terms of reintervention in the infarcted artery
ompared with traditional BMS with no safety concerns.
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